<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-12T07:45:07+08:00</updated>
  <subtitle>世事洞明皆学问，人情练达即文章</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>克服PD-1耐药！祐和医药CD40激动剂联合特瑞普利单抗I/II期研究显示积极抗肿瘤活性</title>
    <updated>2021-01-12T07:25:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/DQf6vO6avWy52eaGQpWwAg</id>
    <link href="https://mp.weixin.qq.com/s/DQf6vO6avWy52eaGQpWwAg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>22亿美元！百济神州与诺华达成替雷利珠单抗授权合作协议</title>
    <updated>2021-01-12T07:25:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/iZtE-OKhWrvga1bqj1G6HQ</id>
    <link href="https://mp.weixin.qq.com/s/iZtE-OKhWrvga1bqj1G6HQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>12月肺癌月报 | 重磅文献18篇，新开关键临床试验12项</title>
    <updated>2021-01-12T07:25:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/qK_QlI6d9RJd-PJXcmpU_w</id>
    <link href="https://mp.weixin.qq.com/s/qK_QlI6d9RJd-PJXcmpU_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>会前通知丨BIO APAC多的是你不知道的事！</title>
    <updated>2021-01-12T07:25:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/gFOeg4T_aukqsmtW8P9ZCA</id>
    <link href="https://mp.weixin.qq.com/s/gFOeg4T_aukqsmtW8P9ZCA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>维昇药业宣布完成1.5亿美元B轮融资，加速大中华区创新内分泌疗法研发</title>
    <updated>2021-01-11T07:45:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/PGj52rppZI0J-hfd9zFAKQ</id>
    <link href="https://mp.weixin.qq.com/s/PGj52rppZI0J-hfd9zFAKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亿腾景昂药业和Aadi Bioscience就ABI-009（西罗莫司白蛋白结合型纳米颗粒）达成大中华区独家授权合作</title>
    <updated>2021-01-11T07:45:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/LLyjH9HLdohUOxufRw6AUA</id>
    <link href="https://mp.weixin.qq.com/s/LLyjH9HLdohUOxufRw6AUA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>领袖汇聚倒计时丨中国肿瘤医药营销趋势论坛—医学分论坛</title>
    <updated>2021-01-11T07:45:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/VARvnnnzNpFucBDn2VENCA</id>
    <link href="https://mp.weixin.qq.com/s/VARvnnnzNpFucBDn2VENCA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>巡礼2021｜从战略到执行，打造BD王者</title>
    <updated>2021-01-11T07:45:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/pVkUJvO_k2uLTX_-zpBtbQ</id>
    <link href="https://mp.weixin.qq.com/s/pVkUJvO_k2uLTX_-zpBtbQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再鼎医药1.75亿美元引进重症肌无力新药！加码布局自身免疫疾病业务</title>
    <updated>2021-01-10T12:57:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/kE7G6TaSRiKVtw8W0cqJ9Q</id>
    <link href="https://mp.weixin.qq.com/s/kE7G6TaSRiKVtw8W0cqJ9Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亘喜生物纳斯达克IPO上市</title>
    <updated>2021-01-10T12:57:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/NIRCRAUD7ZcNsZOQOnMZ5w</id>
    <link href="https://mp.weixin.qq.com/s/NIRCRAUD7ZcNsZOQOnMZ5w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>男女均有效！开拓药业普克鲁胺阻止新冠患者轻症向重症转化，效果显著</title>
    <updated>2021-01-10T12:57:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/GfcsVrVCM_-mOMmANa9eCA</id>
    <link href="https://mp.weixin.qq.com/s/GfcsVrVCM_-mOMmANa9eCA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>江湖你我——2020年国内CRO行业回顾</title>
    <updated>2021-01-09T10:29:12+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-09:/s/EU7bDGdjlMEXC1b72iLSrg</id>
    <link href="https://mp.weixin.qq.com/s/EU7bDGdjlMEXC1b72iLSrg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【最新综述】胰腺癌免疫疗法的机遇与挑战</title>
    <updated>2021-01-08T07:54:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-08:/s/J54NfmLWqdRIsFTK9UFRjA</id>
    <link href="https://mp.weixin.qq.com/s/J54NfmLWqdRIsFTK9UFRjA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>维昇药业TransCon C-型利钠肽II期中国临床试验申请获批</title>
    <updated>2021-01-08T07:54:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-08:/s/oQIsHk6acYRm0YpPYoufsA</id>
    <link href="https://mp.weixin.qq.com/s/oQIsHk6acYRm0YpPYoufsA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>贝达药业万江：成功的肿瘤药营销重在患者可及，最终塑成品牌、商业双赢</title>
    <updated>2021-01-08T07:54:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-08:/s/4LHn7t31nMlLBMRrwMq3YQ</id>
    <link href="https://mp.weixin.qq.com/s/4LHn7t31nMlLBMRrwMq3YQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一图读懂 | 2020年乳腺癌指南更新，NCCN vs CSCO对比</title>
    <updated>2021-01-08T07:54:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-08:/s/StpAxhKz6TYrZoC2X8gPQw</id>
    <link href="https://mp.weixin.qq.com/s/StpAxhKz6TYrZoC2X8gPQw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年创新药获批最大赢家：诺华</title>
    <updated>2021-01-07T08:08:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/hNNIFrWj2Pz__Qrs__1IRA</id>
    <link href="https://mp.weixin.qq.com/s/hNNIFrWj2Pz__Qrs__1IRA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>降糖药市场TOP10中国公司产品管线对比</title>
    <updated>2021-01-07T08:08:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/qXEDQO3JDxOcS5xCYX4XiQ</id>
    <link href="https://mp.weixin.qq.com/s/qXEDQO3JDxOcS5xCYX4XiQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田副总裁陈杰博士：洞见悬而未决的中国特色临床痛点</title>
    <updated>2021-01-07T08:08:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/BaXPsXsDvFj-iMO09AAsjA</id>
    <link href="https://mp.weixin.qq.com/s/BaXPsXsDvFj-iMO09AAsjA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>注册管理丨给热爱以岁月，给努力以路径</title>
    <updated>2021-01-07T08:08:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/Xa-H6IOr2qtVMgtRaMa7qQ</id>
    <link href="https://mp.weixin.qq.com/s/Xa-H6IOr2qtVMgtRaMa7qQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>